Research: PATZELT-WENCZLER and P

Listed in Issue 57

Abstract

PATZELT-WENCZLER and PONCE-POSCHL, ASTA Medica AG, Weismullerstr. 45, D-60314 Frankfurt am Main, Germany. Dr_Jeannette.Simon@astamedica.de conducted a trial into the efficacy of Kamillosan® cream in atopic eczema.

Background

Kamillosan® cream contains chamomile extract as an active principle manufactured from the chamomile sort Manzana and has been proved not to exhibit a chamomile-related allergen potential. For this reason Kamillosan® cream is suited for local therapy of atopic eczema.

Methodology

In a partially double-blind, randomized study carried out as a half-side comparison, Kamillosan® cream was tested vs. 0.5% hydrocortisone cream and the vehicle cream as placebo in patients suffering from medium-degree atopic eczema.

Results

After a two-week treatment Kamillosan® cream showed a mild superiority towards 0.5% hydrocortisone and a marginal difference as compared to placebo.

Conclusion

References

Patzelt-Wenczler R and Ponce-Poschl E. Proof of efficacy of Kamillosan® cream in atopic eczema. European Journal of Medical Research 5(4): 171-5. Apr 2000.

Comment

There is a large amount of anecdotal writings on the use of chamomile for skin conditions such as eczema so it is good news to see a clinical trial showing that it may be comparable to a hydrocortisone cream.

ICAN 2024 Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

top of the page